Literature DB >> 29740498

MicroRNA-493 inhibits the proliferation and invasion of osteosarcoma cells through directly targeting specificity protein 1.

Ming Qian1, Haiyi Gong1, Xinghai Yang1, Jian Zhao1, Wangjun Yan1, Yan Lou1, Dongyu Peng1, Zhenxi Li1, Jianru Xiao1.   

Abstract

Osteosarcoma (OS) is the most common type of primary bone tumor and accounts for ~60% of all malignant bone tumors in children and adolescents. A large number of studies have proposed that the dysregulated and dysfunctional microRNAs may serve important roles in the occurrence, progression and metastasis of various types of human cancer, including OS. MicroRNA-493 (miR-493) has been identified to act as a tumor suppressor in several types of human cancer. However, little is known regarding the expression pattern and clinical significance of miR-493 in OS. In the present study, reverse transcription-quantitative polymerase chain reaction analysis revealed that miR-493 was markedly downregulated in OS tissues and cell lines and a low miR-493 level were associated with distant metastasis and clinical stage. Furthermore, functional experiments demonstrated that enforced expression of miR-493 led to a significant decrease in OS cell proliferation and invasion in vitro. Furthermore, through bioinformatics analysis, specificity protein 1 (SP1) was identified as a direct target gene of miR-493 in OS. Its expression was upregulated in OS tissues and was negatively associated with miR-493 expression levels. Inhibition of SP1 expression also suppressed the proliferation and invasion of OS, exerting a similar effect to that induced by miR-493 overexpression. These results suggested that miR-493 inhibited OS cell proliferation and invasion through negative regulation of SP1. Therefore, miR-493/SP1 may represent a potential therapeutic target for the treatment of OS.

Entities:  

Keywords:  invasion; microRNA-493; osteosarcoma; proliferation; specificity protein 1

Year:  2018        PMID: 29740498      PMCID: PMC5934716          DOI: 10.3892/ol.2018.8268

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  The evolution of gene regulation by transcription factors and microRNAs.

Authors:  Kevin Chen; Nikolaus Rajewsky
Journal:  Nat Rev Genet       Date:  2007-02       Impact factor: 53.242

Review 3.  Nuclear organization and chromatin dynamics--Sp1, Sp3 and histone deacetylases.

Authors:  James R Davie; Shihua He; Lin Li; Anoushe Sekhavat; Paula Espino; Bojan Drobic; Katherine L Dunn; Jian-Min Sun; Hou Yu Chen; Jenny Yu; Susan Pritchard; Xuemei Wang
Journal:  Adv Enzyme Regul       Date:  2008-03-14

4.  miR‑494 is an independent prognostic factor and promotes cell migration and invasion in colorectal cancer by directly targeting PTEN.

Authors:  Hai-Bing Sun; Xi Chen; Hong Ji; Tao Wu; Hong-Wei Lu; Yan Zhang; Hua Li; Yi-Ming Li
Journal:  Int J Oncol       Date:  2014-09-22       Impact factor: 5.650

Review 5.  Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors.

Authors:  Debabrata Mukhopadhyay; Kaustubh Datta
Journal:  Semin Cancer Biol       Date:  2004-04       Impact factor: 15.707

6.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

7.  A meta-analysis of osteosarcoma outcomes in the modern medical era.

Authors:  Daniel C Allison; Scott C Carney; Elke R Ahlmann; Andrew Hendifar; Sant Chawla; Alex Fedenko; Constance Angeles; Lawrence R Menendez
Journal:  Sarcoma       Date:  2012-03-18

8.  Functional role of post-translational modifications of Sp1 in tumorigenesis.

Authors:  Wen-Chang Chang; Jan-Jong Hung
Journal:  J Biomed Sci       Date:  2012-11-14       Impact factor: 8.410

9.  Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors.

Authors:  Satya Pathi; Indira Jutooru; Gayathri Chadalapaka; Vijayalekshmi Nair; Syng-Ook Lee; Stephen Safe
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

10.  MicroRNA-493 suppresses tumor growth, invasion and metastasis of lung cancer by regulating E2F1.

Authors:  Yixue Gu; Ye Cheng; Ying Song; Zhijie Zhang; Min Deng; Chengkun Wang; Guopei Zheng; Zhimin He
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

View more
  5 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

2.  MiR-1224-5p Activates Autophagy, Cell Invasion and Inhibits Epithelial-to-Mesenchymal Transition in Osteosarcoma Cells by Directly Targeting PLK1 Through PI3K/AKT/mTOR Signaling Pathway.

Authors:  Bo Zhang; Kun Chen; Bicheng Jin; Dongfang Jin; Zhaozhen Zhuo
Journal:  Onco Targets Ther       Date:  2020-11-17       Impact factor: 4.147

3.  Long noncoding RNA KCNQ1 opposite strand/antisense transcript 1 promotes osteosarcoma progression through miR-154-3p/KLF12.

Authors:  Qibo Zhang; Huachang Jiang; Youming Jin; Ning Zhang; Zhihua Mu; Yan Guo; Haitao Li
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

4.  MicroRNA-548b inhibits proliferation and invasion of hepatocellular carcinoma cells by directly targeting specificity protein 1.

Authors:  Haile Qiu; Gehong Zhang; Bin Song; Junmei Jia
Journal:  Exp Ther Med       Date:  2019-07-25       Impact factor: 2.751

5.  MicroRNA-382 inhibits cell growth and migration in colorectal cancer by targeting SP1.

Authors:  Yupeng Ren; Hao Zhang; Peng Jiang
Journal:  Biol Res       Date:  2018-11-24       Impact factor: 5.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.